Legal notice

You are currently on the website www.net4cgd.eu published in the frame of the Net4CGD European consortium by Genethon, a French not-for-profit association organised under the French law of July 1, 1901 and located 1bis rue de l’Internationale, 91002 Evry, France, N° SIREN 402 187 520, Tél: +33(0)1 69 47 28 28. The publishing editor is Anne Galy, from Genethon.
The managing editor is Elodie Noël from Finovatis, a partner in the Net4CGD consortium. Finovatis is a company with a capital of 250.000€, registered with the Registry of Commerce & Companies of Lyon under number n°481 118 388 (adress 68 Cours Lafayette Immeuble Lafayette 69003 Lyon Cedex 03, France Tél. : +33(0)4 78 54 79 40 Fax : +33(0)4 72 33 65 17.
The Website is hosted by Claranet SAS, 18-20, rue du Faubourg du Temple 75011, Paris, France www.claranet.fr/, Tel : +33 (0)826 007 656.

This website :

  • is dedicated to scientific and public communities,
  • presents scientific and medical information on the Net4CGD research program, a large-scale integrating project that has received funding from the European Community’s Seventh Framework Programme (FP7-HEALTH-2012-INNOVATION-1) under grant agreement  305011,
  • ensures the proper promotion and sharing of Net4CGD consortium results and outputs.

Copyright over text and images :

Users of the Net4CGD website agree to respect the intellectual property rights over the content offered on the website and will not :

  • copy, summarize, modify, alter or redistribute, without prior permission from Finovatis any article, title, application, software, logo, brand name, information, illustration or photograph other than for strictly private purposes; this includes copying for professional purposes and mass distribution;
  • reproduce all or part of the website on another website or internal company network.

Photo credits :

  • Inserm Serimedis  www.serimedis.inserm.fr
    • Cell producing a lentivirus - author: Jean-Claude Chermann
    • Monocyte - author : Dimitri Dantchev
    • Circulating monocytes - author: Andrea Cimarelli & Colette Dezutter,
    • Pulmonary aspergillosis - author : Loïc Guillevin,
    • Neutrophil killing bacteria, neutrophil, blood neutrophil - author: Elisabeth Cramer,
    • Removal of bone marrow, lentivirus structure - author : Michel Depardieu,
    • Blood granulocyte surrounded by erythrocytes - author: Claude Féo,
    • Aspergillus fumigates - author: Eveline Guého,
  • Schema of Gene therapy for X-CGD - Courtesy to Manuel Grez
  • Hematopoietic colonies – author AFM/Genethon
  • Laboratory tests – author AFM/Genethon
  • Clinical-grade gene therapy vector– author AFM/Genethon


Graphical and technical design :

Elle&La :  8 rue Lemercier, 75017 Paris, France   
www.elle-et-la.com
www.publicacionestecnicas.com

NET4CGD Newsletter 2017 : Net4CGD Consortium - Gene Therapy for C-CGD

The Net4CGD European Consortium is focused on the clinical development of Gene Therapy as a new Orphan Drug for patients with the X-linked form of Chronic Granulomatous Disease (X-CGD). Patients receive autologous CD34+ blood stem cells transduced with the G1XCGD lentiviral vector.

In Europe, two clinical studies are ongoing: G1XCGD.01 study (NCT01855685) and G1XCGD.02 study (NCT02757911). Three patients have already been treated and results are encouraging.

Notably, a study is also ongoing in USA (NCT02234934) and three patient benefitted from the same therapeutic approach with good tolerance and clinical improvement.

For more information, please refer to the Net4CGD Newsletter 2017 that can be found here.

NET4CGD Newsletter 2016 : Focus on the Gene Therapy Studies for X-CGD

The Net4CGD European Consortium is focused on the clinical development of Gene Therapy as a new Orphan Drug for patients with the X-linked form of Chronic Granulomatous Disease (X-CGD). Patients will receive autologous CD34+ blood stem cells transduced with the G1XCGD lentiviral vector. In 2016, Phase I/II Clinical Trials are ongoing in several clinical centers in Europe. For more information, please refer to the Net4CGD Newsletter 2016 that can be found here.

NET4CGD News  : First CGD patient to be treated - Dana-Farber/Boston Children’s Gene Therapy Programme.

On December 18, 2015, 22-year-old Brenden Whittaker became the first CGD patient to be treated with gene therapy for chronic granulomatous disease (CGD) - Dana-Farber/Boston Children’s Gene Therapy Programme.

Further information can be found on the Boston Children's Hospital website by clicking here.

XCGD Multicentric European Study - Q&A

As part of the NET4CGD dissemination strategy and in order to provide information to patients, a Q&A titled "New gene therapy trial for X-CGD" has been created that can be found on the NET4CGD website under the "NET4CGD Project" tab.

NET4CGD Results In Brief

As the European Commission's primary public repository and portal to disseminate information on all EU-funded research projects and their results in the broadest sense, CORDIS has published a summary on the NET4CGD project. This project summary  is available in several languages (French, English, German, Spanish, Italian and Polish) that can be found on the NET4CGD website under the "NET4CGD Project" tab.

More Articles...